jRCT2051240119招募中不适用
This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 18
- 主要终点
- Incidence of dose-limiting toxicities (DLTs)
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized Controlled Trial
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 130age old under（—）
- 性别
- All
入选标准
- •Provision of formalin-fixed paraffin embedded tissue sample from primary or metastatic disease
- •Karnofsky Performance Score of 60 or more.
- •Histologically proven diagnosis of GBM. Patients who have had RT for low-grade glioma (LGG) or grade 3 glioma and have subsequently relapsed to histologically confirmed GBM can be considered
- •A radiological diagnosis of recurrent/relapsed or progressive disease according to RANO criteria.
- •Completion of first-line radiation at least 6 months prior to Cycle 1 Day
- •Patients with tumor-induced seizures must be well controlled on a stable anti-epileptic treatment
- •Willing to receive anti-epileptic prophylaxis for the duration of study drug administration.
排除标准
- •Administration of chemotherapy or any investigational drug in the 28 days or carmustine (CCNU) or lomustine (BCNU) in the 6 weeks prior to receiving the first dose of treatment in the Japan part.
- •History of severe brain-injury or stroke.
- •Patient not eligible for sequential MRI evaluations are not eligible for this study.
- •History of epileptic disorder or any seizure history unrelated to tumor
- •Treatment with Strong inhibitors or inducers of CYP3A4 within 2 weeks prior to receiving study drug
- •Concurrent therapy with other seizurogenic medications.
- •Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
- •Concurrent severe and/or uncontrolled medical condition (e.g., severe COPD).
- •Prior treatment with pneumotoxic drugs, e.g. busulfan, bleomycin, within the past year. If prior therapy in lifetime, then excluded if history of pulmonary toxicities from administration. Patients who have received treatment with nitrosoureas (e.g., carmustine, lomustine) in the year before study entry without experiencing lung toxicity are allowed on study.
- •History or presence of myopathy or raised creatine kinase (CK) >5 x upper limit of normal (ULN) on 2 occasions at screening.
- •Cardiac dysfunction defined as: Myocardial infarction within six months of study entry, NYHA (New York Heart Association) Class II/III/IV heart failure, unstable angina, unstable cardiac arrhythmias
- •Evidence of severe pulmonary infections, as judged by the investigator (For Japan part only this includes active infection including tuberculosis, chronic active or uncontrolled Hep B or Hep C)
- •With the exception of alopecia, any unresolved toxicities from prior therapy greater than National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE 4.03) Grade 1 at the time of starting study treatment and patients with chronic Grade 2 unresolved toxicities may be eligible Additional exclusion criteria for Arm A and Japan Part
- •Has previously received ATM inhibitor with concurrent RT
结局指标
主要结局
Incidence of dose-limiting toxicities (DLTs)
DLTs will be used to calculate the maximum tolerated dose (MTD). The MTD of AZD1390 is the maximum dose at which <=25% patients experience a DLT.
Incidence of adverse events (AEs) and serious adverse events (SAEs)
For each adverse event CTCAE grade and causality (related to AZD1390 or radiotherapy) will be collected.
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Investigating the safety and tolerability of ONC201 in healthy adults - Part ACancerACTRN12621001002875Chimerix, Inc.15
已完成
1 期
Investigating the safety and tolerability of ONC201 in healthy adults under fasting and fed conditionsCancerACTRN12621000975897Chimerix, Inc.18
已完成
1 期
Investigating the safety and tolerability of ONC201 in healthy adults under fasting and fed conditions - Part 2bCancerACTRN12621001003864Chimerix, Inc.30
进行中（未招募）
不适用
Study to assess the safety and efficacy of Lenalidomide and Ofatumumab combination (Lenofa) in chronic lymphocytic leukenia (CLL) patients relapsed or refractory after fludarabine containing regimensEUCTR2012-000634-20-ITA.O. UNIVERSITARIA INTEGRATA DI VERONA
招募中
1 期
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsNCT06954077Sichuan Baili Pharmaceutical Co., Ltd.45